FOLFOX vs FOLFIRI as Second-line of Therapy After Progression to Gemcitabine/Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer

BACKGROUND: Several progresses have been achieved for first-line chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) with Gem-NabP and FOLFIRINOX extensively used as standard first line regimens. However, the best second-line chemotherapy choice after progression is still not complete...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Cancer Manag Res
Hoofdauteurs: Catalano, Martina, Conca, Raffaele, Petrioli, Roberto, Ramello, Monica, Roviello, Giandomenico
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Dove 2020
Onderwerpen:
Original Research
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7585276/
https://ncbi.nlm.nih.gov/pubmed/33116881
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S267393
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items